UNCOVER-3 5 Year Efficacy and Safety Manuscript Supplemental Materials

Published: 28 January 2021| Version 2 | DOI: 10.17632/rgrg58szs6.2
Contributor:
Andrew Blauvelt

Description

Supplemental materials for "Long-term efficacy and safety of ixekizumab: 5-year analysis of the UNCOVER-3 randomized controlled trial" (JAAD-D-20-01565)

Files

Institutions

Eli Lilly and Co

Categories

Safety, Psoriasis, Efficacy Assessment, Efficacy Study

License